Nothing Special   »   [go: up one dir, main page]

Mahan et al., 2022 - Google Patents

Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis

Mahan et al., 2022

View HTML @Full View
Document ID
16190321484121795947
Author
Mahan T
Wang C
Bao X
Choudhury A
Ulrich J
Holtzman D
Publication year
Publication venue
Molecular neurodegeneration

External Links

Snippet

Background One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β (Aβ) peptide into amyloid plaques. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset AD and has been shown to …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Similar Documents

Publication Publication Date Title
Mahan et al. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis
Kloske et al. The important interface between apolipoprotein E and neuroinflammation in Alzheimer’s disease
Liu et al. ApoE4 accelerates early seeding of amyloid pathology
Gratuze et al. Impact of TREM2 R47H variant on tau pathology–induced gliosis and neurodegeneration
El Hajj et al. Ultrastructural evidence of microglial heterogeneity in Alzheimer’s disease amyloid pathology
Boza-Serrano et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease
Kawakami et al. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy
Alić et al. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
Huynh et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis
Fitz et al. Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice
Choi et al. Autophagy enables microglia to engage amyloid plaques and prevents microglial senescence
Ofengeim et al. RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease
Paolicelli et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss
Pooler et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease
Sagare et al. RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Malnar et al. Bidirectional links between Alzheimer's disease and Niemann–Pick type C disease
Kamp et al. Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
Rauch et al. Changes in brain β-amyloid deposition and aquaporin 4 levels in response to altered agrin expression in mice
Chen et al. Increased tauopathy drives microglia-mediated clearance of beta-amyloid
Jackson et al. Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer’s disease
Thygesen et al. Diverse protein profiles in CNS myeloid cells and CNS tissue from lipopolysaccharide-and vehicle-injected APPSWE/PS1ΔE9 transgenic mice implicate cathepsin Z in Alzheimer’s disease
Wojtas et al. Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation
De Rossi et al. Aberrant accrual of BIN1 near Alzheimer’s disease amyloid deposits in transgenic models
Hussong et al. Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy
Rönnbäck et al. Mitochondrial dysfunction in a transgenic mouse model expressing human amyloid precursor protein (APP) with the Arctic mutation